These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1329621)

  • 41. Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.
    Prosser BL; Beskid G
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):33-45. PubMed ID: 7789095
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of HSR-903, a new quinolone.
    Takahashi Y; Masuda N; Otsuki M; Miki M; Nishino T
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1326-30. PubMed ID: 9174193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.
    Clement JJ; Tanaka SK; Alder J; Vojtko C; Beyer J; Hensey D; Ramer N; McDaniel D; Chu DT
    Antimicrob Agents Chemother; 1994 May; 38(5):1071-8. PubMed ID: 8067740
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro activity of OPC-17116.
    Neu HC; Fang W; Gu JW; Chin NX
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1310-5. PubMed ID: 1329620
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
    Smith KR; Cobbs CG
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):55-8. PubMed ID: 1314175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobes.
    Biedenbach DJ; Jones RN
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1636-42. PubMed ID: 7492122
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibacterial activity of the new quinolone CI-960 (PD 127391) against clinical isolates at a major tertiary care center in Saudi Arabia.
    Qadri SM; Abo-Askar H; Ueno Y
    Chemotherapy; 1992; 38(2):92-8. PubMed ID: 1317281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activity of the new fluoroquinolone CP-99,219.
    Neu HC; Chin NX
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
    Isenberg HD; Alperstein P; France K
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.
    Sato K; Hoshino K; Tanaka M; Hayakawa I; Osada Y
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1491-8. PubMed ID: 1324647
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Drugs Exp Clin Res; 1992; 18(8):311-7. PubMed ID: 1338041
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro antibacterial activities of DQ-113, a potent quinolone, against clinical isolates.
    Tanaka M; Yamazaki E; Chiba M; Yoshihara K; Akasaka T; Takemura M; Sato K
    Antimicrob Agents Chemother; 2002 Mar; 46(3):904-8. PubMed ID: 11850285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
    Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
    Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibacterial properties of AM-1155, a new 8-methoxy quinolone.
    Hosaka M; Kinoshita S; Toyama A; Otsuki M; Nishino T
    J Antimicrob Chemother; 1995 Aug; 36(2):293-301. PubMed ID: 8522459
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
    Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
    J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
    Wise R; Brenwald NP; Andrews JM; Boswell F
    J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.